![Pharvaris NV](/common/images/company/N_PHVS.png)
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications. Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
ZUG, Switzerland, June 11, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and...
Deucrictibant substantially resolved symptoms of an HAE attack in 78.6% participants within 24 hoursHigh treatment satisfaction of deucrictibant driven by favorable effectiveness subdomain score...
ZUG, Switzerland, May 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.59 | 3.27595780122 | 18.01 | 19.09 | 17.69 | 41996 | 18.33512039 | CS |
4 | 0.57 | 3.16139767055 | 18.03 | 20.51 | 16.05 | 46965 | 17.94932295 | CS |
12 | -4.65 | -20 | 23.25 | 25.5 | 15.37 | 63016 | 19.26245754 | CS |
26 | -11.4 | -38 | 30 | 33 | 15.37 | 83694 | 23.66624213 | CS |
52 | 2.2 | 13.4146341463 | 16.4 | 33 | 15 | 87495 | 23.25356301 | CS |
156 | 4.35 | 30.5263157895 | 14.25 | 33 | 1.77 | 220461 | 12.24815209 | CS |
260 | -6.4 | -25.6 | 25 | 42.86 | 1.77 | 200494 | 13.03124902 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.